Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death
|
|
- Ambrose Parsons
- 5 years ago
- Views:
Transcription
1 Nephrol Dial Transplant (2008) 23: doi: /ndt/gfm845 Advanced Access publication 8 December 2007 Original Article Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death Areef Ishani 1,2, Craig A. Solid 1, Eric D. Weinhandl 1, David T. Gilbertson 1, Robert N. Foley 1,2 and Allan J. Collins 1,2 1 Chronic Disease Research Group, Minneapolis Medical Research Foundation, USA and 2 Department of Medicine, University of Minnesota, Minneapolis, MN, USA Abstract Background. A proportion of haemodialysis patients experience periods below target haemoglobin levels due to longer time required to reach the target or to haemoglobin level variability. We aimed to determine the consequences associated with cumulative number of months below target haemoglobin concentrations. Methods. We constructed an incident cohort including patients whose day 91 after dialysis initiation fell between 1 January and 31 December Haemoglobin concentration, erythropoiesis-stimulating agent dose, comorbid condition and hospitalization data were obtained from Medicare claims. Patients were classified by 0, 1, 2 or 3 months with haemoglobin concentration below the K/DOQI target (11 g/dl). Using an inverse probability weighted marginal structural model to adjust for time-varying factors associated with haemoglobin concentration, we determined the association between number of months below target and subsequent risk for hospitalization and mortality. Results. The final cohort included patients who met criteria. Those with more months below haemoglobin target were less likely to have received intravenous iron. More months below target were associated with increased risk of hospitalization (RR 1.70, 95% CI ) and mortality (RR 2.48, 95% CI ). Conclusions. Future interventions should focus on modifiable factors associated with greater time below target haemoglobin concentrations to determine whether altering the time below target can alter the risk of hospitalizations or mortality. Keywords: Erythropoiesis-stimulating agent; haemoglobin level; hospitalization; mortality Correspondence and offprint requests to: Areef Ishani, Chronic Disease Research Group, Minneapolis Medical Research Foundation, 914 South 8th Street, Suite S-253, Minneapolis, MN 55404, USA. Tel: ; Fax: ; AIshani@cdrg.org Introduction Several studies have defined the association between anaemia and adverse health outcomes among haemodialysis patients. Randomized controlled trials have demonstrated an association between anaemia and reduced quality of life and data conflict regarding progression of left ventricular hypertrophy [1 6]. Observational studies have suggested an inverse relationship between haemoglobin concentration, risk of hospitalization and mortality and cost among haemodialysis patients [7 14]. Given the available evidence, the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend a target haemoglobin of at least 11 g/dl among haemodialysis patients [15]. Since publication of these guidelines in 1997, the percentage of patients achieving target haemoglobin concentrations has increased due to earlier initiation, higher doses of erythropoietin and increased use of parenteral iron [16,17]. While overall haemoglobin values have increased, a proportion of incident haemodialysis patients experience periods below target due to longer time required to reach the target level or to haemoglobin level variability [18]. The consequences associated with the cumulative number of months below target haemoglobin concentrations have not been studied extensively. Previous studies have attempted to define the association between time to target haemoglobin concentration and outcomes [13,19]. Using a variety of methodologies, including time-dependent Cox models and propensity scores, these studies have demonstrated that persistently low haemoglobin concentrations are associated with increased risks of hospitalization and mortality. However, in addition to baseline population differences, significant timevarying features influence both the predictor (haemoglobin) and outcomes, leading to potential bias when using conventional analytic techniques such as time-dependent Cox models [20]. Specifically, haemoglobin concentrations over time are influenced by ongoing comorbid conditions, hospitalizations, previous erythropoietin dose and previous haemoglobin concentrations. Current haemoglobin values determine future therapy with erythropoietin and iron. C The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 Haemoglobin targets and hospitalization and mortality risk 1683 Haemoglobin has been demonstrated to be an independent predictor of both hospitalization and survival. The problem of time-dependent confounders, affected by prior treatment, with standard analytic techniques can be addressed using marginal structural modelling (MSM). MSM is a methodology for estimating the causal effect of a timedependent exposure in the presence of time-dependent covariates that may be simultaneous confounders and intermediate variables [21 23]. MSM attempts to create a pseudorandomized population that is balanced on all measured confounders [24]. Unlike randomized controlled trials, which balance on unmeasured confounders, MSM is unable to account for unmeasured confounders. Using MSM, we aimed to estimate if longer time to a threshold haemoglobin value of 11 g/dl in an incident haemodialysis cohort is associated with greater risk of hospitalization and death. Methods We performed a retrospective analysis of incident US haemodialysis patients using data from the United States Renal Data System (USRDS), a national system that collects information on all new dialysis patients in the United States. The information includes comorbid conditions, selected laboratory values and functional status at dialysis initiation. For individuals with Medicare as primary insurance payer, the USRDS obtains Medicare claims data, forming the basis of longitudinal comorbidity adjustment. For individuals receiving erythropoietin, providers are required to report monthly haemoglobin concentrations and erythropoietin dose. The study included patients whose day 91 after haemodialysis initiation fell between 1 January and 31 December 2002 and who did not change renal replacement therapy modality or die before day 91 (n = ). Additionally, we required participants to have Medicare as primary payer on day 91 and to survive for at least 9 months after dialysis initiation, resulting in a final cohort size of (66.8%). Excluded patients tended to be younger (almost 70% aged <65 years) and were more often male, but distributions of race and primary cause of renal failure were similar (data not shown). We defined a patient clock for each individual, a series of exposure periods each with its own follow-up period. The first patient clock began with the first full calendar month after day 91. In MSM, patients are included in multiple, rolling, exposure periods, each with its own follow-up period [21]. Consequently, each individual may be included in multiple, overlapping exposure periods, each with his or her own unique outcome period. In this way, multiple, mutually exclusive outcome periods are analyzed for each patient and are adjusted for demographic characteristics, health encounters (from claims data, including diagnoses and procedures performed) and disease severity in the exposure period before the outcome and at baseline. Exposure months Because erythropoietin claims are required to ascertain haemoglobin levels, only individuals on erythropoietin therapy are included in the cohort. Because haemoglobin levels over multiple months are required to identify a persistent haemoglobin level, participants were required to have erythropoietin claims during a particular exposure period to be included in the analysis for that period. Participants were required to have three sequential months of erythropoietin claims to allow haemoglobin levels to stabilize [25]. Patients with mean haemoglobin values <11 g/dl in a month were identified as having low haemoglobin for that month. The total number of months (three) with low haemoglobin was calculated, giving each participant a score between 0 and 3. Total erythropoietin dose was obtained during the same month as the haemoglobin value, so erythropoietin claims for an additional month were not required of patients in the sample. Haemoglobin values reported in claims data are typically the second-to-last of the billing period; thus, almost all erythropoietin doses on the claims were administered before that haemoglobin measurement. Identifying covariates To establish each patient s expected haemoglobin level for each month, used to determine weights in MSM, hospital admissions and lengths of stay, blood transfusions, intravenous (IV) vitamin D, IV iron and comorbid conditions were identified from Medicare claims data in the period before each exposure month. In an attempt to ensure that patients had adequate exposure for those adjusters without extending the exposure period for too long, we identified hospitalizations, anaemia treatment and comorbid conditions in the 3-month period before the three sequential months of erythropoietin claims. These data together with data obtained from the three sequential months of erythropoietin claims allowed a total exposure duration of 6 months. Due to the relatively short exposure time, comorbid conditions were defined based on a single Part A or Part B claim. Demographic characteristics were obtained from the Identification and Medical Evidence portions of the Centers for Medicare & Medicaid Services (CMS) Renal Beneficiary Utilization System. Dialysis provider characteristics were obtained from the annual CMS end-stage renal disease facility survey. Each patient was linked to a specific dialysis provider through the CMS-assigned provider number. Outcomes Immediately following each exposure period was a 1-month outcome period, during which Medicare Part A claims were searched to identify inpatient hospital admissions, and the CMS Death Notification form (CMS-2746) was used to determine mortality. Hospitalization rates were calculated as the number of inpatient admissions divided by the time at risk during the month, where days already in the hospital were excluded from the time at risk. The time at risk for mortality rates included the entire follow-up month up to the date of death, regardless of whether or not the patient was in the hospital. Individuals were followed for up to 2 years after initiation, giving a total of 15 possible exposure/outcome periods. Thus, once individuals were defined as eligible for cohort entry, months 1 through 3 were used to define time-varying comorbid conditions (in addition to baseline information).
3 1684 A. Ishani et al. Months 4 through 6 were defined as the exposure period during which haemoglobin concentrations and erythropoietin doses were defined, and month 7 was used to define outcomes. For the next rolling period, months 2 through 4 were used to define time-varying comorbid conditions, months 5 through 7 were used to define haemoglobin concentrations and erythropoietin doses and month 8 was used to define outcomes. This rolling patient-clock methodology pattern continued until the end of study follow-up (15 periods). Estimation in MSM involves multiple steps. The first is obtaining the weights for each month of haemoglobin values, which was done by using logistic regression to obtain a propensity for each patient to have a low haemoglobin in that month given the adjusters obtained during the exposure period and the observed haemoglobin for the month. That was repeated for each month with a haemoglobin value in every exposure period for which that patient was included. Next, we constructed a marginal structural logistic model (to obtain odds ratios) and a marginal structural Poisson model (to obtain rate ratios) on the pooled set of rolling exposure/outcome periods, using the weights for each patient in each exposure period included in the total follow-up time, and information from the baseline time period. As estimates from the Poisson model are similar to those from the logistic model, only the logistic model is presented. Results The final study cohort included incident haemodialysis patients. Table 1 presents the total number of patients included in each of 15 identified exposure/outcome periods after applying the inclusion criteria (alive, on haemodialysis with Medicare as primary payer, and 3 months of erythropoietin claims) for each period. The final cohort is representative of individuals undergoing haemodialysis in the USA in demographic characteristics, primary cause of end-stage renal disease and dialysis unit characteristics (Table 2). In Table 1. Numbers of eligible patients per 6-month exposure period (study cohort n = ) Inclusion criteria Remained On haemodialysis with Valid erythropoietin Period alive Medicare as primary payer claims Table 2. Demographic variables (n = ) Variable N Percent Age (years) < to to Race White Black Other/unknown Gender Male Female Primary cause of ESRD Diabetes Hypertension Other/unknown Dialysis unit characteristics Profit status For-profit Non-profit Unknown Location Urban Rural Unknown Affiliation Chain Hospital Independent Unknown ESRD: end-stage renal disease. general, patients with persistently low haemoglobin levels had higher disease prevalence than those with at least 1 month with a haemoglobin level of at least 11 g/dl (Table 3). Patients with persistently low haemoglobin levels were the minority (Figure 1) as most patients respond to erythropoietin therapy within 2 to 3 months. Interestingly, those with persistently low haemoglobin levels seemed less likely to have received IV iron compared with those with haemoglobin levels >11 g/dl (Table 4). IV vitamin D use was similar in frequency and pattern across haemoglobin groups. Blood transfusions were rare, but slightly more common for patients with persistently low haemoglobin levels (data not shown). Unadjusted outcomes As expected, hospitalization and mortality were more common among patients with persistently low haemoglobin and increased steadily with increasing number of months with haemoglobin <11 g/dl. Regardless of the measure (raw mortality, relative mortality, raw hospitalization, hospitalization rate per time at risk) each additional month with low haemoglobin was associated with worse outcomes (Table 5). Even before adjusting for other covariates and employing MSM, these results demonstrate that, compared with patients with no months <11 g/dl, those with 3 months <11 g/dl were hospitalized more than twice as frequently and were between three and four times more likely to die during the follow-up month (Figures 2 and 3).
4 Haemoglobin targets and hospitalization and mortality risk 1685 Table 3. Comorbid conditions, exposure periods 1 through 15 Months Average across Months Average across Condition <11 g/dl periods a Condition <11 g/dl periods a Atherosclerotic heart disease COPD Congestive heart failure Gastrointestinal bleeding Cerebrovascular accident Liver disease Peripheral vascular disease Dysrhythmia Cardiac (other) Cancer COPD: chronic obstructive pulmonary disease. a Values are percents. Fig. 1. Percent of patients in each haemoglobin (Hb) group by a 6-month exposure period. Table 4. Percent of patients receiving no IV iron during exposure periods, by period and number of months with low haemoglobin Exposure period Months <11g/dL
5 1686 A. Ishani et al. Fig. 2. Percent of patients who died during the follow-up month by the number of months with haemoglobin <11.0 g/dl (0 month or 3 months). Adjusted outcomes The adjusted MSMs also demonstrate that persistently low haemoglobin is associated with increased risk of hospitalization and mortality (Table 6). Compared with patients with no months <11 g/dl, those with 3 months <11 g/dl were 1.8 times more likely to be hospitalized and almost 2.5 times more likely to die during the follow-up month. Additionally, the confidence intervals for each additional month s effect do not overlap, indicating that each additional month with a haemoglobin level below target adds to the cumulative risk of adverse outcome. Finally, when we substituted total erythropoietin dose in place of haemoglobin concentration, our results did not change. There was a significant, positive association between erythropoietin dose and the risk of hospitalization and mortality. This is not unexpected, as higher erythropoietin doses are highly correlated with low haemoglobin levels. Discussion We demonstrate, using an incident haemodialysis cohort, that 40% of patients require at least 1 month after day 91 on dialysis to achieve the lower limit of the K/DOQI haemoglobin targets. Additionally, in unadjusted analysis, those with more months below the target haemoglobin concentration were less likely to have received IV iron in the preceding months. We also demonstrate a progressive relationship between the number of months below the target haemoglobin concentration of 11 g/dl and the risk of hospitalization and mortality in the subsequent month. These results persisted in a marginal structural model that allows adjustment for differences in characteristics at baseline and for time-varying factors (ongoing illness and erythropoietin dose) related to both haemoglobin values and outcomes. Table 5. Percent, relative percent and relative rate of mortality and hospitalization by period and number of months with low haemoglobin Months Average <11 g/dl across periods Death (percent) Any hospitalization (percent) Hospitalization relative rate, unadjusted Specifically, each additional month with a haemoglobin concentration <11 g/dl was associated with progressive non-overlapping risk of hospitalization and mortality using both logistic regression and Poisson MSM models. Several factors have been associated with intractable anaemia and, to a lesser extent, require more time to reach target haemoglobin levels [18,26]. Institutional variability in anaemia care is a large, potentially modifiable factor associated with the inability to achieve target haemoglobin concentrations. For example, a recent study using a Medicare sample demonstrated that between 67 and 81% of individuals achieve the lower boundary of the K/DOQI haemoglobin target [27]. This variability is likely due in large part to institutional policies that are likely modifiable [28]. Use of catheters for vascular access has been associated with higher EPO doses, lower haemoglobin concentrations and increased risk of intractable anaemia [18,29]. Several mechanisms have been postulated to explain this association, including a higher risk of infection [30 39], an
6 Haemoglobin targets and hospitalization and mortality risk 1687 Fig. 3. Unadjusted hospitalization rate (per 100 patient-months) during the follow-up month by the number of months with haemoglobin <11.0 g/dl (0 month or 3 months). Table 6. Adjusted odds ratios from history-adjusted, time-dependent marginal structural models Outcome Months <11 g/dl Odds ratio 95% lower confidence limit 95% upper confidence limit P Death 0 Reference < < < Hospitalization 0 Reference < < < inflammatory state resulting from placement of the access [40] and possibly poor dialysis [41 44], though this mechanism is controversial. While iron administration in haemodialysis patients has increased steadily over time, a percentage remain who do not receive it; lack of IV iron has been associated with intractable anaemia (defined as at least 5 of 6 months with haemoglobin <11 g/dl) [18]. We confirm this finding by demonstrating that individuals with more time with haemoglobin concentrations below target were less likely to have received IV iron in the preceding months. These three factors, institutional variability, catheter use and lack of IV iron, represent opportunities for improvement in anaemia management. Future randomized controlled trials should determine if modification of these factors can decrease the time below target haemoglobin concentrations, and specifically if this reduction decreases the incidence of adverse outcomes. Numerous observational studies have suggested an inverse association between achieved haemoglobin concentration and risk of hospitalization, morbidity and mortality among dialysis patients [7 14]. These studies, along with modifications in CMS erythropoietin reimbursement, have led to widespread erythropoietin use among dialysis patients [45]. Recently, proposed haemoglobin concentration targets have come under question, especially the upper end of the K/DOQI target range ( 13 g/dl). The CREATE [46] and CHOIR [47] studies attempted to determine if higher haemoglobin concentrations were associated with improved outcomes in CKD patients not requiring dialysis. Neither study was able to demonstrate a benefit to higher haemoglobin concentrations and both suggested harm associated with higher haemoglobin concentrations. However, both studies have flaws [48]. While we have demonstrated that more months below the haemoglobin target of 11 g/dl are associated with greater risk of hospitalization and mortality, caution should be taken in applying our results, as any attempt to decrease the number of months below haemoglobin target may have the unintended consequence of exceeding the upper haemoglobin target, thereby potentially increasing adverse health outcomes. Our results are based on retrospective observational data and have all the limitations associated with retrospective registry studies. We attempted to mitigate these limitations by using extensive observational data and by using a new methodology for controlling baseline and time-varying confounding (MSM). Additionally, we used different models (logistic regression and Poisson) and multiple rolling exposure/outcome time periods. The main benefit of using
7 1688 A. Ishani et al. MSM is that results derived from this methodology more closely estimate the results of an intent-to-treat trial. However, this holds only under the assumption of no unmeasured confounders, which is likely not the case. For example, while we are able to adjust for the presence of comorbid conditions, we were unable to adjust for their severity. Similarly we were unable to adjust for factors for which we had no information, such as type of vascular access or inflammatory state, an important limitation of all multivariable models. Further, MSMs can lead to bias if the model used to obtain the propensity-score-based weights is incorrectly specified, or if the structural model of the MSM itself is incorrectly parameterized. An additional limitation of our study is the number of individuals who were ineligible to be included in our final cohort. Reasons for exclusion included primary insurance payer other than Medicare, haematocrit concentrations not reported to Medicare, not being on erythropoietin therapy, or infrequent haematocrit determination. Whether inclusion of these individuals would have altered our results, or whether our observations are generalizable to those excluded, is unknown. We demonstrate that greater time below the lower K/DOQI haemoglobin target is associated with increased risk of hospitalization and mortality in an incident haemodialysis cohort. Future interventions should target modifiable factors associated with a greater number months below target haemoglobin concentrations to determine if altering the time below target haemoglobin can alter the risk of hospitalizations or mortality. Acknowledgements. The authors thank Chronic Disease Research Group colleagues Shane Nygaard, BA, for manuscript preparation and Nan Booth, MSW, MPH, for manuscript editing. This study was supported by a research contract from Roche Laboratories, Nutley, NJ, USA. The contract provides for the authors to have final determination of the manuscript content. Conflict of interest statement. Areef Ishani, Craig A. Solid and Eric D. Weinhandl have no conflicts of interest with the subject matter of this study. David T. Gilbertson, Robert N. Foley and Allan J. Collins have received consulting fees from Roche. References 1. Cannella G, La Canna G, Sandrini M et al. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 1991; 6: Fellner SK, Lang RM, Neumann A et al. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 1993; 44: Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: London GM, Zins B, Pannier B et al. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 1989; 36: Pascual J, Teruel JL, Moya JL et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35: Silberberg J, Racine N, Barre P et al. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: Churchill DN, Muirhead N, Goldstein M et al. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol 1995; 43: Collins AJ, Li S, Ebben J et al. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 2000; 36: Ma J, Ebben J, Xia H et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: Madore F, Lowrie E, Brugnara C et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 1997; 8: Ofsthun N, Labrecque J, Lacson E et al. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003; 63: Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: Robinson BM, Joffe MM, Berns JS et al. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 2005; 68: Xia H, Ebben J, Ma J et al. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10: National Kidney Foundation-Dialysis Outcomes Quality Initiative. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997; 30: S192 S St Peter WL, Obrador GT, Roberts TL et al. Trends in intravenous iron use among dialysis patients in the United States ( ). Am J Kidney Dis 2005; 46: Collins AJ, Ma JZ, Xia H et al. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 1998; 32(Suppl 4): S133 S Kausz AT, Solid C, Pereira BJ et al. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease? Am J Kidney Dis 2005; 45: Ishani A, Guo H, Gilbertson DT et al. Time to target haemoglobin concentration (11 g/dl) risk of hospitalization and mortality among incident dialysis patients. Nephrol Dial Transplant 2007; 22: Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004; 15: Robins JM. Correction for non-compliance in equivalence trials. Stat Med 1998; 17: Robins JM. Proceedings of the Section on Bayesian Statistical Science. Alexandria, VA: American Statistical Association. 1998, Robins JM. In: Halloran E, Berry D (eds). Statistical Models in Epidemiology: the Environment and Clinical Trials. New York: Springer, 1999, Cole SR, Hernan MA, Robins JM et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003;158: U.S. Renal Data System (USRDS) Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006, Fink J, Blahut S, Reddy M et al. Use of erythropoietin before the initiation of dialysis and its impact on mortality. AmJKidneyDis 2001; 37: Collins AJ, Roberts TL, St Peter WL et al. United States Renal Data System assessment of the impact of the National Kidney Foundation- Dialysis Outcomes Quality Initiative guidelines. AmJKidneyDis 2002; 39: Fink JC, Hsu VD, Zhan M et al. Center effects in anemia management of dialysis patients. J Am Soc Nephrol 2007; 18: Roberts TL, Obrador GT, St Peter WL et al. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int 2004; 66: Churchill DN, Taylor DW, Cook RJ et al. Canadian Hemodialysis Morbidity Study. Am J Kidney Dis 1992; 19:
8 Haemoglobin targets and hospitalization and mortality risk Powe NR, Jaar B, Furth SL et al. Septicemia in dialysis patients: incidence, risk factors, and prognosis. Kidney Int 1999; 55: Marr KA, Kong L, Fowler VG et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int 1998; 54: Dobkin JF, Miller MH, Steigbigel NH. Septicemia in patients on chronic hemodialysis. Ann Intern Med 1978; 88: Hoen B, Paul-Dauphin A, Hestin D et al. EPIBACDIAL:Amulticenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: Kairaitis LK, Gottlieb T. Outcome and complications of temporary haemodialysis catheters. Nephrol Dial Transplant 1999; 14: Bonomo RA, Rice D, Whalen C et al. Risk factors associated with permanent access-site infections in chronic hemodialysis patients. Infect Control Hosp Epidemiol 1997; 18: Muirhead N, Hodsman AB. Occult infection and resistance of anaemia to rhuepo therapy in renal failure. Nephrol Dial Transplant 1990; 5: Macdougall I, Coles G, Williams J. Inhibition of a response to erythropoietin in the presence of infection or malignancy. Erythropoiesis 1992; 3: Ishani A, Collins AJ, Herzog CA et al. Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. Kidney Int 2005; 68: NKF-K/DOQI Clinical practice guidelines for vascular access: update Am J Kidney Dis 2001; 37: S137 S Athirakul K, Schwab SJ, Twardowski ZJ et al. What is the role of permanent central vein access in hemodialysis patients? Semin Dial 1996; 9: Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. NEnglJMed1996; 334: Sehgal AR, Snow RJ, Singer ME et al. Barriers to adequate delivery of hemodialysis. Am J Kidney Dis 1998; 31: Dhingra RK, Young EW, Hulbert-Shearon TE et al. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 2001; 60: Powe NR, Griffiths RI, Anderson GF et al. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients. Am J Kidney Dis 1993; 22: Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: Levin A. Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 2007; 22: Received for publication: Accepted in revised form:
Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients
Kidney International, Vol. 65 (2004), pp. 626 633 Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients SUYING LI and ALLAN J. COLLINS Nephrology
More informationRecombinant human erythropoietin (EPO) is an effective
Septicemia in Patients with ESRD Is Associated with Decreased Hematocrit and Increased Use of Erythropoietin Allen R. Nissenson,* Michelle L. Dylan, Robert I. Griffiths, Hsing-Ting Yu, and Robert W. Dubois
More informationHematocrit Level and Associated Mortality in Hemodialysis Patients
J Am Soc Nephrol 10: 610 619, 1999 Hematocrit Level and Associated Mortality in Hemodialysis Patients JENNIE Z. MA,* JIM EBBEN, HONG XIA, and ALLAN J. COLLINS* *Division of Nephrology, Hennepin County
More informationHematocrit Levels and Hospitalization Risks in Hemodialysis Patients
J Am Soc Nephrol 10: 1309 1316, 1999 Hematocrit Levels and Hospitalization Risks in Hemodialysis Patients HONG XIA,* JIM EBBEN,* JENNIE Z. MA, and ALLAN J. COLLINS *Nephrology Analytical Services, Minneapolis
More informationThe use of surrogates as key performance indicators
REPLY The use of surrogates as key performance indicators Dr José Vinhas Department of Nephrology, Centro Hospitalar de Setúbal. Setúbal, Portugal Received for publication: 24/08/2012 Accepted: 31/08/2012
More informationComparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics
Gilbertson et al. BMC Nephrology 2013, 14:44 RESEARCH ARTICLE Open Access Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics
More informationIN THE LAST few decades, several important
Anemia Management for Hemodialysis Patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) Guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) Findings Francesco Locatelli, MD, Ronald
More informationA rationale for an individualized haemoglobin target
Nephrol Dial Transplant (2002) 17 [Suppl 6 ]: 2 7 A rationale for an individualized haemoglobin target Norman Muirhead University of Western Ontario, London, Ontario, Canada Abstract Despite the use of
More informationErythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
ORIGINAL ARTICLE Nephrology http://dx.doi.org/1.3346/jkms.216.31.1.55 J Korean Med Sci 216; 31: 55- Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease Sun
More informationChronic kidney disease: The distribution of health care dollars
Kidney International, Vol. 66 (2004), pp. 313 321 Chronic kidney disease: The distribution of health care dollars WENDY L. ST.PETER,SAMINA S. KHAN,JAMES P. EBBEN, BRIAN J.G. PEREIRA, and ALLAN J. COLLINS
More informationMaintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study
original article http://www.kidney-international.org & 2008 International Society of Nephrology Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationTRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA
& TRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA 2002-2008 Halima Resić* 1, Enisa Mešić 2 1 Clinic for Hemodialysis, University of Sarajevo Clinics Centre, Bolnička 25, 71000 Sarajevo, Bosnia
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More informationOriginal Article. Introduction
Nephrol Dial Transplant (2004) 19: 121 132 DOI: 10.1093/ndt/gfg458 Original Article Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationErythropoietins Data Points #4
Trends in the utilization of erythropoiesis-stimulating agents among Medicare beneficiaries with kidney disease Erythropoietins Data Points #4 Chronic renal disease affects more than 26 million Americans
More informationEnd-Stage Renal Disease in the United States: An Update from the United States Renal Data System
End-Stage Renal Disease in the United States: An Update from the United States Renal Data System Robert N. Foley and Allan J. Collins United States Renal Data System Coordinating Center, Minneapolis, Minnesota
More informationAgroup of clinicians, researchers, ... REPORT... Chronic Kidney Disease: Stating the Managed Care Case for Early Treatment
... REPORT... Chronic Kidney Disease: Stating the Managed Care Case for Early Treatment Discussion and Consensus of Presentations of Economic Analyses, Managed Care Organization Case Studies, and Opportunities
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationAssociation of Hemoglobin Variability and Mortality among Contemporary Incident Hemodialysis Patients
Association of Hemoglobin Variability and Mortality among Contemporary Incident Hemodialysis Patients Steven M. Brunelli,* Katherine E. Lynch,* Elizabeth D. Ankers, Marshall M. Joffe, Wei Yang, Ravi I.
More informationComment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.
Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
More informationDialysis outcomes: can we do better?
Dialysis outcomes: can we do better? Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director, Chronic Disease Research Group Minneapolis Medical Research Foundation Director,
More informationBecause of important technologic advances achieved over
Anemia and Heart Failure in Chronic Kidney Disease Francesco Locatelli, Pietro Pozzoni, and Lucia Del Vecchio Cardiovascular disease is mainly responsible for the poor long-term survival observed in chronic
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationThe Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.1.55 The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival Seoung Gu Kim 1 and Nam Ho Kim 2 Department of Internal Medicine,
More informationFULFILLMENT OF K/DOQI GUIDELINES 92 anemia treatment dialysis therapy vascular access
INTRODUCTION ANEMIA TREATMENT hemoglobin levels epo treatment iron treatment FULFILLMENT OF K/DOQI GUIDELINES 2 anemia treatment dialysis therapy vascular access EPO DOSING PATTERNS 4 epo dosing per kg
More informationTransfusion Burden among Patients with Chronic Kidney Disease and Anemia
Transfusion Burden among Patients with Chronic Kidney Disease and Anemia Elizabeth V. Lawler,* Brian D. Bradbury, Jennifer R. Fonda,* J. Michael Gaziano,* and David R. Gagnon* *Massachusetts Veterans Epidemiology
More information2011 Dialysis Facility Report
Purpose of the Report 2011 Dialysis Facility Report Enclosed is the 2011 Dialysis Facility Report (DFR) for your facility, based on data from the Centers for Medicare & Medicaid Services (CMS). This DFR
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationChanges in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin
http://www.kidney-international.org & 11 International Society of Nephrology see commentary on page 265 Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate
More informationPOOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS
POOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS CHARLES A. HERZOG, M.D., JENNIE Z. MA, PH.D., AND ALLAN J. COLLINS, M.D. ABSTRACT Background Cardiovascular
More informationImpact of correction of anemia on major complication of chronic renal diseases
Original article: Impact of correction of anemia on major complication of chronic renal diseases Md Hamid Ali, Atanu Roy Chaudhry, Kapildev Mondal, Arijit Sinha Department of General Medicine, Murshidabad
More informationAn economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis
Nephrol Dial Transplant (2013) 28: 413 420 doi: 10.1093/ndt/gfs487 Advance Access publication 25 November 2012 An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Intermediate Outcome
Quality ID #328 (NQF 1667): Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10 g/dl National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL
More information2011 Dialysis Facility Report SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE Dialysis Facility Report SAMPLE
Purpose of the Report Enclosed is the (DFR) for your facility, based on data from the Centers for Medicare & Medicaid Services (CMS). This DFR includes data specific to CCN(s): 999999 These data could
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (1999) 14 [Suppl 2]: 29 36 Chairman s Workshop Report Nephrology Dialysis Transplantation What are the short-term and long-term consequences of anaemia in CRF patients? Department
More information2008 Dialysis Facility Report
iii Purpose of the Report Enclosed is the (DFR) for this facility, based on data from the Centers for Medicare & Medicaid Services (CMS). This DFR includes data specific to provider number(s): 102844 These
More informationmean hemoglobin 11 g/dl (110 g/l) compared to patients with lower mean hemoglobin values (Table 20).
S44 Figure 53 depicts the trend in Epoetin dosing from the 1998 study period to the 2003 study period, with an increasing mean weekly Epoetin dose (units/kg/wk) for patients prescribed Epoetin in lower
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationEvaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases.
Evaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases. Arif Sami Malik FICMS. Abstract Background:Correction of anemia as a result of renal
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationTitle: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review
Title: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review Date: 14 February 2008 Context and policy issues: Anemia is a complication of chronic diseases and commonly occurs in
More informationCurrent situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationSex-specific association of time-varying haemoglobin values with mortality in incident dialysis patients
Nephrol Dial Transplant (2010) 25: 2715 2722 doi: 10.1093/ndt/gfq101 Advance Access publication 26 February 2010 Sex-specific association of time-varying haemoglobin values with mortality in incident dialysis
More informationBlood transfusions in kidney transplant candidates are common and associated with adverse outcomes
Clin Transplant 2011: 25: 653 659 DOI: 10.1111/j.1399-0012.2011397.x ª 2011 John Wiley & Sons A/S. Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes Ibrahim
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationAPPROPRIATE USE OF ERYTHROpoiesis-stimulating
ORIGINAL CONTRIBUTION Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients M. Alan Brookhart, PhD Sebastian Schneeweiss, MD, ScD Jerry Avorn, MD Brian D. Bradbury,
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationDedicated outpatient vascular access center decreases hospitalization and missed outpatient dialysis treatments
http://www.kidney-international.org & 2006 International Society of Nephrology original article Dedicated outpatient vascular access center decreases hospitalization and missed outpatient dialysis treatments
More informationImpact of pre-transplant anaemia correction and erythropoietin resistance on long-term graft survival
Nephrol Dial Transplant (2005) 20 [Suppl 8]: viii8 viii12 doi:10.1093/ndt/gfh1110 Impact of pre-transplant anaemia correction and erythropoietin resistance on long-term graft survival Mariarosaria Campise
More informationREIMBURSEMENT AND ITS IMPACT ON YOUR DIALYSIS PROGRAM Tony Messana Executive Director Renal Services St. Joseph Hospital - Orange
REIMBURSEMENT AND ITS IMPACT ON YOUR DIALYSIS PROGRAM Tony Messana Executive Director Renal Services St. Joseph Hospital - Orange Agenda History of the Medicare ESRD Program Cost of Care for ESRD Patients
More informationChapter 6: Mortality. Introduction 2016 USRDS ANNUAL DATA REPORT VOLUME 2 ESRD IN THE UNITED STATES
Chapter 6: Mortality In 2014, adjusted mortality rates for ESRD, dialysis, and transplant patients, were 136, 166, and 30, per 1,000 patient-years, respectively. By dialysis modality, mortality rates were
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationErythropoietin Friend or Foe in Chronic Kidney Disease Anemia: An Analysis of Randomized Controlled Trials, Observational Studies and Meta-analyses
BJMP 2009:2(3) 12-20 Review Article Erythropoietin Friend or Foe in Chronic Kidney Disease Anemia: An Analysis of Randomized Controlled Trials, Observational Studies and Meta-analyses analyses Amir Hayat
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationAJNT. Original Article
. 2012 May;5(2):81-6 Original Article AJNT Reaching Target Hemoglobin Level and Having a Functioning Arteriovenous Fistula Significantly Improve One Year Survival in Twice Weekly Hemodialysis Sarra Elamin
More informationChapter Five Clinical indicators & preventive health
Chapter Five Clinical indicators & preventive health The painter who draws merely by practice and by eye, without any reason, is like a mirror which copies every thing placed in front of it without being
More informationRegional variability in anaemia management and haemoglobin in the US
Nephrol Dial Transplant (2003) 18: 147 152 Original Article Regional variability in anaemia management and haemoglobin in the US Donal N. Reddan 1, Diane L. Frankenfield 2, Preston S. Klassen 1, Joseph
More informationChapter six Outcomes: hospitalization & mortality. There is an element of death in life, and I am astonished
INTRODUCTION 1 OVERALL HOSPITALIZATION & MORTALITY 1 hospital admissions & days, by primary diagnosis & patient vintage five-year survival mortality rates, by patient vintage expected remaining lifetimes
More informationManaging fluid status of dialysis patients remains a
Hospital Treatment for Fluid Overload in the Medicare Hemodialysis Population Thomas J. Arneson,* Jiannong Liu,* Yang Qiu,* David T. Gilbertson,* Robert N. Foley,* and Allan J. Collins* *Chronic Disease
More informationPrevalence of cardiovascular damage in early renal disease
Nephrol Dial Transplant 2001) 16 wsuppl 2x: 7±11 Prevalence of cardiovascular damage in early renal disease Adeera Levin University of British Columbia, Renal Insuf ciency Clinic, Vancouver, Canada Abstract
More informationIntercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients
Clinical Nephrology, Vol. 71 No. 4/2009 (397-404) Intercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients Original 2009 Dustri-Verlag Dr. K. Feistle ISSN
More informationImpact of Timing of Initiation of Dialysis on Mortality
J Am Soc Nephrol 14: 2305 2312, 2003 Impact of Timing of Initiation of Dialysis on Mortality SRINIVASAN BEDDHU,* MATTHEW H. SAMORE, MARK S. ROBERTS, GREGORY J. STODDARD, NIRUPAMA RAMKUMAR, LISA M. PAPPAS,
More informationImprovement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 24, 2008 Matthew J. Novak, 1 Heena Sheth, 2 Filitsa H. Bender, 1 Linda Fried, 1,3 Beth Piraino 1 Improvement in Pittsburgh Symptom Score Index After Initiation of
More informationChapter 9: Cardiovascular Disease in Patients With ESRD
Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in adult ESRD patients, with atherosclerotic heart disease and congestive heart failure being the most common conditions
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationWHEN (AND WHEN NOT) TO START DIALYSIS. Shahid Chandna, Ken Farrington
WHEN (AND WHEN NOT) TO START DIALYSIS Shahid Chandna, Ken Farrington Changing Perspectives Beta blockers 1980s Contraindicated in heart failure Now mainstay of therapy HRT 1990s must Now only if you have
More informationEffects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes
Original Investigation Effects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes Eduardo Lacson Jr, MD, MPH, Weiling Wang, MS, Cari DeVries, Keith
More informationState Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE
Dear State Surveyor: State Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE This report is designed to provide a comparative summary of treatment patterns and patient outcomes for
More informationDisparities in Provision of Transplant Education by Profit Status of the Dialysis Center
American Journal of Transplantation 2012; 12: 3104 3110 Wiley Periodicals Inc. C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2012.04207.x
More informationDialysis Initiation and Optimal Vascular Access: Outcomes and Mortality
Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality Shannon H. Norris, BSN, RN June 6, 2018 Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality DISCUSSION: End Stage
More information2010 Dialysis Facility Report
Purpose of the Report 2010 Dialysis Facility Report Enclosed is the 2010 Dialysis Facility Report (DFR) for this facility, based on data from the Centers for Medicare & Medicaid Services (CMS). This DFR
More informationPeer Kidney Care Initiative
Patient Populations Hospitalizations Mortality Cardiovascular Benchmarks Peer Kidney Care Initiative Peer Report Dialysis Care & Outcomes in the United States, 216 Financial support for the Peer Kidney
More informationAnemia is very common among end-stage renal fail LATEST STRATEGY IN RENAL ANEMIA MANAGEMENT IN PERITONEAL DIALYSIS PATIENTS.
Proceedings of the 3rd Asian Chapter Meeting of the ISPD November 22 24, 2007, Hiroshima, Japan Peritoneal Dialysis International, Vol. 28 (2008), Supplement 3 0896-8608/08 $3.00 +.00 Copyright 2008 International
More informationHemodialysis therapy has been one of the true success
Dialysis Outcomes as a Measure of Adequacy of Dialysis Michael Butman and Allen R. Nissenson Truly adequate dialysis would restore patients to full health, with functional status and length of life indistinguishable
More informationMORTALITY IN PATIENTS ON DIALYSIS AND TRANSPLANT RECIPIENTS
MORTALITY IN PATIENTS ON DIALYSIS AND TRANSPLANT RECIPIENTS COMPARISON OF MORTALITY IN ALL PATIENTS ON DIALYSIS, PATIENTS ON DIALYSIS AWAITING TRANSPLANTATION, AND RECIPIENTS OF A FIRST CADAVERIC TRANSPLANT
More informationTHE ADVANCED CHRONIC KIDNEY DISEASE MANAGEMENT TOOLKIT
THE ADVANCED CHRONIC KIDNEY DISEASE MANAGEMENT TOOLKIT Approximately 20 million Americans have some degree of kidney disease 1 demonstrated by decreased glomerular filtration rate (GFR) (
More informationData Mining Performance in Identifying the Risk Factors of Early Arteriovenous Fistula Failure in Hemodialysis Patients
International Journal of Hospital Research 2012, 2(1):49-54 www.ijhr.iums.ac.ir RESEARCH ARTICLE Data Mining Performance in Identifying the Risk Factors of Early Arteriovenous Fistula Failure in Hemodialysis
More informationPRE-dialysis survey on anaemia management
Nephrol Dial Transplant (2003) 18: 89 100 Original Article PRE-dialysis survey on anaemia management Fernando Valderrábano 1,y, Walter H. Hörl 2, Iain C. Macdougall 3,Jérôme Rossert 4, Boleslaw Rutkowski
More informationLate Creation of Vascular Access for Hemodialysis and Increased Risk of Sepsis
J Am Soc Nephrol 15: 1936 1942, 2004 Late Creation of Vascular Access for Hemodialysis and Increased Risk of Sepsis MATTHEW J. OLIVER,* DEANNA M. ROTHWELL, KINWAH FUNG, JANET E. HUX,* and CHARMAINE E.
More informationThe new FDA label for erythropoietin treatment: How does it affect hemoglobin target?
review http://www.kidney-international.org & 2007 International Society of Nephrology The new FDA label for erythropoietin treatment: How does it affect hemoglobin target? S Fishbane 1 and AR Nissenson
More informationSupplementary Online Content
Supplementary Online Content Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova N. Trends in infective endocarditis in California and New York State, 1998-2013. JAMA. doi:10.1001/jama.2017.4287
More informationDialysis Dose and Body Mass Index Are Strongly Associated with Survival in Hemodialysis Patients
J Am Soc Nephrol 13: 1061 1066, 2002 Dialysis Dose and Body Mass Index Are Strongly Associated with Survival in Hemodialysis Patients FRIEDRICH K. PORT, VALARIE B. ASHBY, RAJNISH K. DHINGRA, ERIK C. ROYS,
More informationDose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
Adv Ther (2013) 30:1007 1017 DOI 10.1007/s25-013-0063-y ORIGINAL RESEARCH Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study Peter Choi Mourad
More informationStages of chronic kidney disease
For mass reproduction, content licensing and permissions contact Dowden Health Media. Jonathan J. Taliercio, DO Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio talierj@ccf.org
More informationOriginal Article INTRODUCTION
Original Article The effect of Vitamin D administration on treatment of anemia in end-stage renal disease patients with Vitamin D deficiency on hemodialysis: A placebo-controlled, double-blind clinical
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury In 2015, 4.3% of Medicare fee-for-service beneficiaries experienced a hospitalization complicated by Acute Kidney Injury (AKI); this appears to have plateaued since 2011
More informationRole of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): 18-22 Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**,
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury Introduction In recent years, acute kidney injury (AKI) has gained increasing recognition as a major risk factor for the development of chronic kidney disease (CKD). The
More informationHome Hemodialysis or Transplantation of the Treatment of Choice for Elderly?
Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly? Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University
More informationPneumonia in incident dialysis patients the United States Renal Data System
NDT Advance Access published November 19, 2007 Nephrol Dial Transplant (2007) 1 of 7 doi:10.1093/ndt/gfm474 Original Article Pneumonia in incident dialysis patients the United States Renal Data System
More informationChapter 6: Healthcare Expenditures for Persons with CKD
Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial
More informationpatient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62
introduction 58 < increasing complexity of the patient population 6 < epo use & anemia in the pre-esrd period 62 < biochemical & physical characteristics at initiation 64 < estimated gfr at intiation &
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)
Last Updated: Version 4.3 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Readmission Measures Set
More information